19 min
Season 2 - Episode 1: What's happened since Season 1 Micro-dosing with Zeifmans: Short podcasts on demystifying the business of psychedelics
-
- Business
Welcome back to Micro-dosing with Zeifmans - Season 2! Join our host, Larry Zeifman and this week's guests, Doug Drysdale, CEO of Cybin and Josh Bartch, Co-founder, Chairman & CEO of Mydecine Innovation Group, as they provide an industry update from where we left off at the end of season 1.
Have questions or want to learn more? Contact us direct at info@zeifmans.ca.
About Zeifmans
Zeifmans is a full-service tax, accounting and consulting firm based in Toronto, Canada, ranked as one of Canada’s top 20 firms by revenue. Beyond the traditional offering, our services include business advisory, valuation, corporate finance, transaction services, corporate turnaround and insolvency, and estate and succession planning, supporting our 9,000+ clients through every step of the business life cycle. For more on our services relating directly to the cannabis and psychedelics industry, visit zeifmans.ca.
About Cybin
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
About Mydecine Innovation Group
Mydecine Innovations Group™️ (NEO: MYCO) (OTC:MYCOF) (FSE:0NFA) is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada.are (non-psychedelic) medicinal mushrooms.
The mandate of this SAB continues to provide strategic guidance and direction for Mydecine’s clinical trials for PTSD, underpinned by pure data research, therapy, and scientific programs, advise on intellectual property; and, contribute commentary on Mydecine’s telehealth platform, Mindleap Health™.
Mydecine has also successfully completed multiple acquisitions since its inception.
Welcome back to Micro-dosing with Zeifmans - Season 2! Join our host, Larry Zeifman and this week's guests, Doug Drysdale, CEO of Cybin and Josh Bartch, Co-founder, Chairman & CEO of Mydecine Innovation Group, as they provide an industry update from where we left off at the end of season 1.
Have questions or want to learn more? Contact us direct at info@zeifmans.ca.
About Zeifmans
Zeifmans is a full-service tax, accounting and consulting firm based in Toronto, Canada, ranked as one of Canada’s top 20 firms by revenue. Beyond the traditional offering, our services include business advisory, valuation, corporate finance, transaction services, corporate turnaround and insolvency, and estate and succession planning, supporting our 9,000+ clients through every step of the business life cycle. For more on our services relating directly to the cannabis and psychedelics industry, visit zeifmans.ca.
About Cybin
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
About Mydecine Innovation Group
Mydecine Innovations Group™️ (NEO: MYCO) (OTC:MYCOF) (FSE:0NFA) is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada.are (non-psychedelic) medicinal mushrooms.
The mandate of this SAB continues to provide strategic guidance and direction for Mydecine’s clinical trials for PTSD, underpinned by pure data research, therapy, and scientific programs, advise on intellectual property; and, contribute commentary on Mydecine’s telehealth platform, Mindleap Health™.
Mydecine has also successfully completed multiple acquisitions since its inception.
19 min
Top Podcasts In Business